Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
C5a Receptor Inhibitor (ANCA Vasculitis)

Avacopan

Brand names: Tavneos

Avacopan is an oral complement C5a receptor antagonist used, with a rituximab- or cyclophosphamide-based regimen, to treat severe active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis).

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively blocks the C5a receptor on neutrophils, reducing complement-driven neutrophil activation and recruitment that underlie the vascular inflammation of ANCA-associated vasculitis.

Prescribing in practice

  • Avoid in active or untreated significant hepatic disease and monitor liver function, as serious hepatotoxicity has been reported and may require interruption or discontinuation.
  • It is used to reduce reliance on glucocorticoids rather than as monotherapy, alongside standard immunosuppression, with the attendant infection risk including hepatitis B reactivation screening.
  • Avoid strong CYP3A4 inducers, which lower avacopan exposure, and use caution with strong inhibitors.

Monitoring

Monitor liver function tests before and regularly during treatment, and remain vigilant for serious infection.

Counselling the patient

  • Report yellowing of the skin or eyes, dark urine or unusual tiredness promptly.
  • Tell any clinician you are on immune-suppressing treatment, and report signs of infection.
  • Take the capsules as directed with food.

Evidence & guidelines

Avacopan's role in ANCA-associated vasculitis is based on the ADVOCATE trial and is recommended by NICE within specialist regimens.

Reference: Jayne et al. NEJM 2021 (ADVOCATE trial); MHRA SPC Tavneos; NICE TA757 (avacopan for GPA/MPA); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways